Drugs / AZD7745
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07612813 | Jun 2026 → Sep 2027 expected | staphylococcus aureus infection | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD7745 | “AZD7760, a mAb combination of suvratoxumab (labeled as MEDI4893) and AZD7745” NCT07612813 ↗ |
| Modality | Monoclonal antibody | “AZD7760, a mAb combination of suvratoxumab (labeled as MEDI4893) and AZD7745” NCT07612813 ↗ |